Results 61 to 70 of about 4,117 (197)
International Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo +11 more
wiley +1 more source
Update on biologic and small molecules treatments in pediatric allergic diseases
Pediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker +10 more
wiley +1 more source
Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes +6 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta +2 more
wiley +1 more source
Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela +2 more
wiley +1 more source
Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis
JPGN Reports, Volume 7, Issue 3, Page 449-451, August 2026.Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley +1 more source
Prurigo nodularis of Hyde treated with low-dose thalidomide. [PDF]
, 2009 Prurigo nodularis of Hyde is a skin disorder characterized by pruritic excoriated nodules. Improvement in pruritus and decrease in nodules was demonstrated in patients treated with oral thalidomide 200-400 mg daily.
RENNA, S, COTTONE, Mario, ORLANDO, A
core
The Journal of Dermatology, Volume 53, Issue 8, Page 1099-1114, August 2026.ABSTRACT Clinical phenotypes of atopic dermatitis (AD) can vary, with some individuals displaying difficult‐to‐treat prurigo nodularis‐like lesions. We aimed to assess the real‐world disease burden and treatment course of Japanese adults with AD‐associated prurigo nodules (AD‐Pn) receiving conventional AD treatments.
Yoko Kataoka +8 more
wiley +1 more source
Abrocitinib for Severe Atopic Dermatitis and Prurigo Nodularis: An Indian Case Series
Clinical Dermatology ReviewAbrocitinib is a second generation selective JAK 1 inhibitor. It is the newest addition to the armamentarium of atopic dermatitis (AD). It was recently approved by US FDA for the management of severe atopic dermatitis in patients who were refractory to ...
Geetha K +2 more
doaj +1 more source